The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000419.4:c.3060+2T>C

CA290944108

627296 (ClinVar)

Gene: ITGA2B
Condition: Glanzmann's thrombasthenia
Inheritance Mode: Autosomal recessive inheritance
UUID: 87ce3bc8-52e8-4b5a-bc39-f9db1ce33a75
Approved on: 2020-09-04
Published on: 2021-08-20

HGVS expressions

NM_000419.4:c.3060+2T>C
ENST00000262407.6:c.3060+2T>C
ENST00000648408.1:n.2374+307T>C
ENST00000262407.5:c.3060+2T>C
ENST00000587295.5:n.253+1481T>C
ENST00000588098.1:n.37+307T>C
ENST00000592462.5:n.2761T>C
NM_000419.3:c.3060+2T>C
NM_000419.5:c.3060+2T>C
NC_000017.11:g.44374352A>G
CM000679.2:g.44374352A>G
NC_000017.10:g.42451720A>G
CM000679.1:g.42451720A>G
NC_000017.9:g.39807246A>G
NG_008331.1:g.20154T>C
More

Pathogenic

Met criteria codes 4
PM2_Supporting PVS1_Strong PM3_Supporting PP4_Strong

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Platelet Disorders VCEP
The NM_000419.4:c.3060+2T>C variant is a splice site variant that causes aberrant splicing and results in the deletion of 38 amino acids in the transmembrane domain (PMID: 9215749). It is present in a very low frequency in gnomAD (0.00003876). It is seen in four individuals in the compound heterozygous state in the published literature. In summary, based on the available evidence at the time the c.3060+2T>C variant is classified as pathogenic. GT-specific criteria applied: PVS1_Strong, PM2_Supporting, PP4_Strong, PM3_Supporting.
Met criteria codes
PM2_Supporting
The variant is reported in 5/128992 non-Finnish European alleles, at a frequency of 0.00003876 in gnomAD. This is lower than the threshold of <1/10000 alleles and meets PM2.
PVS1_Strong
The variant results in alternative splicing and an in-frame deletion of 38 amino acids in the transmembrane domain which is critical to protein function (PMID: 25617834).
PM3_Supporting
The variant is seen in trans with Cys705Arg (classified as Pathogenic by the ClinGen Platelet Disorders VCEP, 0.5pt), c.3092_3093dup (not considered here to avoid circularity), Ile596Thr (classified as VUS, does not meet PM2 0pt) and Asp396Asn (not included to avoid circularity) in four unrelated probands. A total of 0.5 pts is applied that meets PM3_Supporting.
PP4_Strong
Compound heterozygous individual, GT9, from PMID: 25373348 meets criteria for PP4_strong with bleeding symptoms, impaired platelet aggregation in response to collagen, ADP, AA, adrenaline, epinephrine but near-normal response to ristocetin. Western blotting and flow cytometry revealed reduced integrin expression. Full sequencing of both ITGA2B and ITGB3 was performed. [1 unpublished individual heterozygous for this variant from internal laboratory data, does not meet PP4: 10yo female with history of easy bruising, gingival bleeding, iron deficiency anemia and seizure. She had an inconsistently high PFA but never with both epinephrine and ADP being abnormal at the same draw. Platelet count, PT, aPTT, and VWF studies were normal. Decreased expression levels of αIIbβ3 observed on flow cytometry, consistent with heterozygous state. The individual was tested with the "platelet function disorder" panel.]
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.